Modafinil: Pharmacology and therapeutic perspectives;Le modafinil: Pharmacologie et perspectives thérapeutiques

Revue Neurologique

Volumn 159, Issue 1, 2003, Pages 122-125

  Billiard, M ^a  

^a GUI DE CHAULIAC HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

MODAFINIL;

CIRCADIAN RHYTHM; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; NARCOLEPSY; REVIEW; SLEEP DISORDER; TREATMENT CONTRAINDICATION;

BENZHYDRYL COMPOUNDS; CENTRAL NERVOUS SYSTEM STIMULANTS; CLINICAL TRIALS; FATIGUE; HUMANS; NARCOLEPSY; SLEEP DISORDERS;

EID: 0037220288     PISSN: 00353787     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (16)

1. BILLIARD M, BESSET A, MONTPLAISIR J, LAFFONT F, GOLDENBERG F, WEILL JS, LUBIN S. (1994). Modafinil: a double blind multicentric study. Sleep, 17: S107-S112.
2. BROUGHTON RJ, FLEMING JAE, GEORGE CFP, et al. (1997). Randomized, double-blind, placebo-controlled crossover trial of modafinil in the treatment of excessive daytime sleepiness in narcolepsy. Neurology, 49: 444-451.
3. CHEMELLI RM, WILLIE JT, SINTON CM, et al. (1999). Narcolepsy in orexin knock-out mice: molecular genetics of sleep regulation. Cell, 98: 437-451.
4. DAMIAN MS, GERLACH BS, SCHMIDT F, LEHMANN BS E, REICHMANN H. (2001). Modafinil for excessive daytime sleepiness in myotonic dystrophy. Neurology, 56: 794-796.
5. HAUSER RA, WAHBA MN, ZESIEWICZ TA, MCDOWELL ANDERSON W. (2000). Modafinil treatment of pramipexole-associated somnolence. Mov Disord, 15: 1269-1271.
6. LIN JS, Hou Y, JOUVET M. (1996). Potential brain neuronal targets for amphetamine, methyphenidate, and modafinil-induced wakefulness, evidenced by c-fos immunochemistry in the cat. Nat Acad Sci USA, 93: 14128-14133.
7. LYNN J, RAMMOHAN K, BECK JJ, POLLACK, NAGARAJA HN, BLUMENFELD A, ROSENBERG J. (2000). Efficacy and safety of provigil (Modafinil) for the treatment of fatigue in patients with multiple sclerosis (MS). Abstract from the Annual Meeting of the Consortium of Multiple Sclerosis Centers, June 22-25, Halifax, Nova Scotia, Canada.
8. MOACHON G, KANMACHER I, CLENET M, MATINER D. (1996). Pharmacokinetic profile of modafinil. Drugs of today, 32: 23-33.
9. NICOLLET A, DAUVILLIERS Y, ONDZE B, VERGNE C, SEGURET F, BILLIARD M. (2000). Treatment of narcolepsy with modafinil: a long-term open study in 244 patents. Neurology, 54: A19.
10. NISHINO S, MAO J, SAMPATHKUMARAN R, SHELTON J. (1998). Increased dopaminergic transmission mediates the wake-promoting effects of cns stimulants. Sleep Res Online, 1: 49-61.
11. th World Congress on Sleep Apnea, March 12-15, Sydney, Australia.
12. RISTANOVIC RK, HAYDUK R, MITLER MM. (2000). Long-term efficacy, safety, and dosing profile of provigil (Modafinil) for the treatment of excessive daytime sleepiness associated with narcolepsy. Sleep, 23: A304.
13. th World Congress on Sleep Apnea, March 12-15, Sydney, Australia.
14. TERZOUDI M, PANAGIOTA G, HEILAKOS G, VISVIKI K, KARAGEORGIOU CE. (2000). Fatigue in multiple sclerosis: evaluation and a new pharmacological approach. Neurology, 54: A61.
15. US MODAFINIL IN NARCOLEPSY STUDY GROUP. (1998). Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy. Ann Neurol, 43: 88-97.
16. WISOR JP, NISHINO S, SORA I, UHL GH, MIGNOT E, EDGAR DM. (2001). Dopaminergic role in stimulant-induced wakefulness. J. Neurosci, 21: 1787-1794.